On February 26, 2025 Mabqi reported the company secures a €5 million non-dilutive financing from the France 2030 public investment plan to advance preclinical development of it’s lead antibody candidate MQI-201 in oncology (Press release, Mabqi, FEB 26, 2025, View Source [SID1234651774]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We are thrilled to announce a €5 million funding as part of the "Innovations in Biotherapies and Bioproduction" call for projects under the France 2030 public investment plan program, managed by BpiFrance.

This non-dilutive funding will accelerate the development of a patented first-in-class antibody for the treatment of metastatic prostate cancer, one of the most common cancers in the world.

Mabqi develops a first-in-class MQI-201 antibody specifically targeting the TRPV6 ion channel, an innovative therapeutic target in oncology. This funding will enable Mabqi to launch the bioproduction of this antibody, regulatory IND-enabling studies and FIH trial. We target a Phase I clinical study early 2027.

MQI-201 antibody candidate is the result of a close collaboration with SATT Nord and INSERM teams in Lille. It has already shown excellent tolerance and high efficacy in vivo prostate cancer models and could, in the long term, be used in combination with standard prostate cancer treatments.

Mabqi aims at discovering 2 antibodies candidates per year thanks to its proprietary human antibody library combined to an AI-powered phage & yeast display platform.